분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-02-14 12:12:34 , Hit : 1268
 Genzyme, Voyager Launch Up-to-$845M Gene Therapy Collaboration


GEN News Highlights
More »
Feb 11, 2015


        Genzyme, a Sanofi company, and Voyager Therapeutics said today they have launched an up-to-$845 million collaboration to develop and commercialize new adeno-associated virus (AAV) gene therapies for CNS disorders.

The partnership is designed to combine Genzyme’s expertise in AAV gene therapy with Voyager’s AAV product engine, with the goal of commercializing multiple gene therapy programs—including programs for Parkinson’s disease, Friedreich’s ataxia, and Huntington’s disease, as well as other CNS disorders. Genzyme and Voyager said their collaboration portfolio will combine programs and intellectual property from both companies.

Under their gene-therapy alliance, Voyager will oversee research and development activities for all programs, while Genzyme will have the option to license several programs following completion of an initial proof-of-concept human clinical trial.

Voyager will retain all U.S. rights to its lead product programs in Parkinson’s disease (VY-AADC01) and Friedreich’s ataxia (VY-FXN01), with Genzyme holding outside-U.S. rights. VY-AADC01 is in an ongoing Phase Ib study by Voyager with collaboration partners at the University of California, San Francisco; all of Voyager’s other gene therapy programs are in preclinical phases.

Voyager will split U.S. profits with Genzyme for the Huntington’s disease program (VY-HTT01).  However, Voyager retains worldwide rights to its lead amyotrophic lateral sclerosis (ALS) program (VY-SOD101), which is not part of the collaboration.

Genzyme has agreed to pay Voyager $100 million upfront—to consist of $65 million in cash, a $30 million equity investment in Voyager, and additional unspecified in-kind contributions. Voyager will also be eligible for future potential development and sales milestone payments of up to $745 million, as well as tiered royalties on product sales.

“This strategic collaboration provides significant funding to drive the development of our expanded product pipeline, while also allowing Voyager to continue to thrive as an independent company,” Steven Paul, M.D., Voyager’s president and CEO since September 2014, said in a statement.

Headquartered in Cambridge, Mass., Voyager is a private company launched in 2014 with $45 million in Series A venture capital financing from Third Rock Ventures.








1027   인간배아 DNA편집을 둘러싼 논란  이성욱 2015/03/17 1024
1026   상처 치유 관련 미스터리 이해  이성욱 2015/03/17 946
1025   First U.S. biosimilar is not considered interchangeable  이성욱 2015/03/11 997
1024   Drug flushes out hidden AIDS virus  이성욱 2015/03/07 1053
1023   숙주 세포와는 별도로 그 활성을 조절하는 HIV  이성욱 2015/03/03 1185
1022   세균이 위협을 기억하는데 도움을 주는 바이러스 절단 효소  이성욱 2015/02/25 1256
1021   iPS세포 '미니 간' 대량생산장치 개발  이성욱 2015/02/23 1042
1020   Paying for gene therapy: are annuities the next big thing?  이성욱 2015/02/22 1021
1019   부모의 특징을 자식에게 전달하는 방식: 박테리아의 DNA  이성욱 2015/02/19 1109
  Genzyme, Voyager Launch Up-to-$845M Gene Therapy Collaboration  이성욱 2015/02/14 1268
1017   진화와 질병치료 연구를 진전시킬 새로운 유전 메커니즘  이성욱 2015/02/06 1072
1016   영국 의회, `세 부모 아기` 합법화  이성욱 2015/02/06 1035
1015   텔로미어 연장을 통해 인간 세포의 노화시계를 되돌리는 데 성공  이성욱 2015/02/04 1519
1014   네안데르탈인과 이웃에 살았던 현생인류의 두개골 발견  이성욱 2015/02/03 1095
1013   종양 미세환경에서 T 세포의 작용을 억제하는 PD-1  이성욱 2015/01/30 2624
1012   인류의 역사를 고스란히 보여주는 결핵균의 게놈  이성욱 2015/01/21 1109
1011   역풍 맞은 사이언스 논문 - 암은 대부분 운이 나빠 발생한다?  이성욱 2015/01/21 1242
1010   최초의 바이오시밀러 약물, 미국 시장에 출시  이성욱 2015/01/16 1197
1009   Novartis taps into gene editing for next generation drugs  이성욱 2015/01/09 1464
1008   저온에서 더 잘 복제되는 감기바이러스  이성욱 2015/01/08 1448

[이전 10개] [1]..[11][12] 13 [14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN